{"id":1001078,"date":"2026-09-08T07:36:32","date_gmt":"2026-09-08T11:36:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/"},"modified":"2026-09-08T07:36:32","modified_gmt":"2026-09-08T11:36:32","slug":"medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/","title":{"rendered":"Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company"},"content":{"rendered":"

\nCompany prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect\u00ae and Teverelix\u00ae indications
\n<\/h2>\n
\n

PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (\u201cMedicus\u201d or the \u201cCompany\u201d), a precision-guided biotech\/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today provided a strategic update highlighting its transformation into a precision oncology-led biotechnology company, anchored by the advancement of CD228V, a second-generation CD228-targeted antibody-drug conjugate (\u201cADC\u201d), while pursuing capital-efficient strategic partnerships to advance clinical development opportunities across its SkinJect\u00ae and Teverelix\u00ae Programs.<\/p>\n

\n CD228V<\/strong>
\n now represents<\/strong> the\u00a0principal strategic priority for Medicus,<\/strong> with initial development concentrated on establishing clinical proof-of-concept in a carefully selected tumor population, supported by an integrated clinical and translational strategy. Based on the existing biological, translational and clinical foundation,\u00a0melanoma represents a compelling initial development opportunity<\/strong>, particularly in patients with relapsed or refractory disease.<\/p>\n

The addition of\u00a0CD228V<\/strong> represents a paradigm shift in Medicus\u2019 clinical development portfolio and establishes precision oncology as a central component of the Company\u2019s strategy.<\/p>\n

CD228V is a second-generation ADC targeting melanotransferrin\/CD228 in solid tumors. The program is supported by an active U.S. Investigational New Drug (IND), a first-in-human Phase 1 clinical study (NCT06799533), and substantial prior scientific, translational, and clinical development.<\/p>\n

The Company believes successful demonstration of clinical proof-of-concept in melanoma, supported by an integrated translational and biomarker strategy, could provide an important foundation for subsequent development in other CD228-expressing solid tumors.<\/p>\n

At the same time, Medicus is sharpening the development strategies for its two other therapeutic programs.<\/p>\n

For\u00a0SkinJect\u00ae<\/strong>, the Company believes the strongest risk-adjusted opportunity lies in Gorlin syndrome rather than broad sporadic\/nodular Basal Cell Carcinoma (BCC) lesions. FDA has authorized initiation of SKNJCT-005, the Company\u2019s NDA-enabling registrational Phase 2b study in patients with Gorlin syndrome presenting with multiple BCCs. Gorlin syndrome is a rare autosomal dominant disease in which patients can develop numerous BCC lesions throughout their lifetime, frequently requiring repeated surgical or other lesion-directed procedures.<\/p>\n

The Company believes concentrating SkinJect\u00ae<\/strong> development on Gorlin syndrome could provide several potential strategic advantages beyond the more broadly competitive sporadic BCC market, which could include approvals for Orphan Drug Designation (\u201cODD\u201d) and Rare Pediatric Disease (\u201cRPD\u201d) designation<\/strong> by the FDA as well as favorable rare-disease-anchored net pricing.<\/p>\n

For\u00a0Teverelix\u00ae<\/strong>, Medicus intends to prioritize the optimized approximately 126-patient Phase 2 acute urinary retention (\u201cAUR\u201d) program and PRECISION-E2<\/strong>, the Phase 2a study in women with symptomatic endometriosis, while continuing to advance the scientific and strategic positioning of Teverelix\u00ae in advanced prostate cancer (\u201cAPC\u201d) through potential partnerships.<\/p>\n

The Company believes this focused portfolio strategy provides multiple opportunities for meaningful clinical and shareholder value creation while enabling the Company to concentrate capital on programs with the most compelling near-term risk-adjusted potential.<\/p>\n

\n Management Commentary:<\/strong>\n <\/p>\n

\n \u201cMedicus has undergone a significant transformation this year,\u201d stated\u00a0<\/em>
\n
\n Dr. Raza Bokhari, Executive Chairman & CEO of Medicus.<\/em>
\n <\/strong>
\n \u201cOur objective is increasingly clear. We are concentrating our capital and organizational resources on programs where we believe focused clinical development and <\/em>
\n execution may create the greatest value and improve patient outcomes, while using strategic partnerships and other capital-efficient structures to preserve and unlock the potential value of other programs. <\/em>
\n We believe that our primary focus on precision oncology substantially enhances our long-term growth profile and positions the Company to participate in one of the most dynamic sectors of biotechnology.\u201d<\/em>\n <\/p>\n

\n For further information contact:<\/strong>\n <\/p>\n

Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com<\/u><\/a>\u00a0\u00a0<\/p>\n

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicuspharma.com<\/u><\/a><\/p>\n

\n
\n About Medicus Pharma Ltd.<\/em>
\n <\/strong>\n <\/p>\n

\n Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech\/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is actively engaged in multiple countries across three continents.<\/em>\n <\/p>\n

\n The Company\u2019s current therapeutic assets are:<\/em>\n <\/p>\n

\n
\n CD228V ADC, an investigational antibody-drug conjugate molecule utilizing Pfizer\u2019s established vedotin linker-payload platform<\/em>
\n <\/strong>
\n , directed against melanotransferrin (CD228), a cell-surface protein expressed across multiple solid tumor types, such as melanoma, squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and esophageal cancer.<\/em>\n <\/p>\n

\n
\n SkinJect<\/em>
\n <\/strong>\u00ae, an <\/em><\/strong>investigational<\/em><\/strong> novel localized immuno-oncology precision product<\/em><\/strong> focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) lesions in <\/em>Gorlin Syndrome patients<\/em><\/strong>, a rare autosomal dominant disease also called nevoid BCC syndrome.<\/em><\/p>\n

\n
\n Teverelix\u00ae, an <\/em>
\n <\/strong>
\n
\n investigational<\/em>
\n <\/strong>
\n
\n next-generation GnRH antagonist,<\/em>
\n <\/strong>
\n is being developed as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients, patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate<\/em>
\n and symptomatic endometriosis.<\/em>\n <\/p>\n

\n
\n Cautionary Notice on Forward-Looking Statements<\/em>
\n <\/strong>\n <\/p>\n

\n Certain information in this news release constitutes “forward-looking statements” or \u201cforward-looking information\u201d within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws (collectively, \u201cforward-looking statements\u201d). “Forward-looking statements” are defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company\u2019s co-development with Pfizer with respect to CD228V and the anticipated benefits thereof, the Company\u2019s plans and expectations relating to the development, manufacture and commercialization of CD228V across human therapeutic indications, the timing, design, conduct and results of any future clinical study of CD228V, including the Company\u2019s plans to initiate clinical development in melanoma, the Company\u2019s intention to focus initial development on melanoma, with potential subsequent development in squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and esophageal cancer, and to evaluate additional indications and lines of therapy; the potential market opportunities related to CD228V, SkinJect\u00ae and Teverelix\u00ae and the Company\u2019s other therapeutic assets, and the development, advancement and commercialization thereof; the Company\u2019s prioritization of CD228V and its related strategic and capital-allocation decisions, including its evaluation of strategic, partnership and other funding opportunities; the initiation, timing, design, conduct and results of the SKNJCT-005 registrational Phase 2b study and whether the results of that study will be sufficient to support the submission of a new drug application; the initiation, timing, design, conduct and results of the Company\u2019s approximately 126-patient Phase 2 study in acute urinary retention and of PRECISION-E2, the Phase 2a study in women with symptomatic endometriosis; whether the FDA will grant Orphan Drug Designation or Rare Pediatric Disease designation for SkinJect\u00ae in Gorlin Syndrome and the benefits of any such designation, if granted; the potential pricing of, and reimbursement for, SkinJect\u00ae, if approved; the Company\u2019s expectations regarding potential clinical and shareholder value creation and the sufficiency and allocation of its capital resources; and the Company\u2019s ability to identify, negotiate and consummate strategic partnerships for SkinJect\u00ae and for Teverelix\u00ae in advanced prostate cancer on acceptable terms or at all. Forward-looking statements are often, but not always, identified by the use of such terms as “may”, \u201con track\u201d, \u201caim\u201d, “might”, “will”, “will likely result”, \u201ccould,\u201d \u201cdesigned,\u201d “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, \u201cpotential\u201d or the negative and\/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2025, and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.<\/em>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect\u00ae and Teverelix\u00ae indications PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (\u201cMedicus\u201d or the \u201cCompany\u201d), a precision-guided biotech\/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today provided a strategic update highlighting its transformation into a precision oncology-led biotechnology company, anchored by the advancement of CD228V, a second-generation CD228-targeted antibody-drug conjugate (\u201cADC\u201d), while pursuing capital-efficient strategic partnerships to advance clinical development opportunities across its SkinJect\u00ae and Teverelix\u00ae Programs. CD228V now represents the\u00a0principal strategic priority for Medicus, with initial development concentrated on establishing clinical proof-of-concept in a carefully selected tumor population, supported by an integrated … <\/p>\n

Continue reading “Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1001078","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMedicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect\u00ae and Teverelix\u00ae indications PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (\u201cMedicus\u201d or the \u201cCompany\u201d), a precision-guided biotech\/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today provided a strategic update highlighting its transformation into a precision oncology-led biotechnology company, anchored by the advancement of CD228V, a second-generation CD228-targeted antibody-drug conjugate (\u201cADC\u201d), while pursuing capital-efficient strategic partnerships to advance clinical development opportunities across its SkinJect\u00ae and Teverelix\u00ae Programs. CD228V now represents the\u00a0principal strategic priority for Medicus, with initial development concentrated on establishing clinical proof-of-concept in a carefully selected tumor population, supported by an integrated … Continue reading "Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-08T11:36:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMjU2NSM3ODIxNDAyIzIzMDUxNzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company\",\"datePublished\":\"2026-09-08T11:36:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\\\/\"},\"wordCount\":1379,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMjU2NSM3ODIxNDAyIzIzMDUxNzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\\\/\",\"name\":\"Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMjU2NSM3ODIxNDAyIzIzMDUxNzk=\",\"datePublished\":\"2026-09-08T11:36:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMjU2NSM3ODIxNDAyIzIzMDUxNzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMjU2NSM3ODIxNDAyIzIzMDUxNzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/","og_locale":"en_US","og_type":"article","og_title":"Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - Market Newsdesk","og_description":"Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect\u00ae and Teverelix\u00ae indications PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (\u201cMedicus\u201d or the \u201cCompany\u201d), a precision-guided biotech\/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today provided a strategic update highlighting its transformation into a precision oncology-led biotechnology company, anchored by the advancement of CD228V, a second-generation CD228-targeted antibody-drug conjugate (\u201cADC\u201d), while pursuing capital-efficient strategic partnerships to advance clinical development opportunities across its SkinJect\u00ae and Teverelix\u00ae Programs. CD228V now represents the\u00a0principal strategic priority for Medicus, with initial development concentrated on establishing clinical proof-of-concept in a carefully selected tumor population, supported by an integrated … Continue reading \"Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-08T11:36:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMjU2NSM3ODIxNDAyIzIzMDUxNzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company","datePublished":"2026-09-08T11:36:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/"},"wordCount":1379,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMjU2NSM3ODIxNDAyIzIzMDUxNzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/","name":"Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMjU2NSM3ODIxNDAyIzIzMDUxNzk=","datePublished":"2026-09-08T11:36:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMjU2NSM3ODIxNDAyIzIzMDUxNzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMjU2NSM3ODIxNDAyIzIzMDUxNzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicus-pharma-advances-transformation-into-a-precision-oncology-led-biotechnology-company\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1001078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1001078"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1001078\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1001078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1001078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1001078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}